PI3K Inhibitors for HR+ Metastatic Breast Cancer

3 Views
administrator
administrator
07/03/23

Panelists Adam M. Brufsky, MD, PhD; José Baselga, MD, PhD; Carlos L. Arteaga, MD; Debu Tripathy, MD; and Denise A. Yardley, MD, discuss the potential for use of PI3K inhibitors buparlisib, alpelisib, and taselisib and their anticipation of data coming in the near future for breast cancer.

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next